My initial thoughts, for what they are worth :1) A raise at .08c...

My initial thoughts, for what they are worth :

1) A raise at .08c is disappointing, I was expecting .11 ( or around there ). Hard to raise cash at the moment. Particularly disappointing with the last 2 raises at .30c, and FDA approval for Pulse achieved since then. Dilution, with options, will take us to ~320M SOI ... 70M more than I had on my calculations.
On the plus side ... money has been committed, and CardieX is back in the game. Let's get 2023 into the rear vision mirror ASAP and turn the ship around in 2024.

2) The accompanying presentation was as per the AGM ... with a few little extra's. I remain optimistic about the companies tech, the vascular biomarker opportunity and the path ahead.

3) The prospectus has the detail of the amended balance sheet, with CliniChain income, proceeds from raise etc. It looks far better than the annual accounts. Will see $11M cash after the raise, current liabilities of $3.6M, of which only $1.1M is in trade & payables, with $2.4M moved to the promissory note, non-current liability.




So a far better position leading into CY 2024.

So, no doubt the next few months will be ugly as the SP drops to the raise price of .08, or less ( IMO )
However, if they are able to execute the activity set as planned ( and I'm backing this high quality team ( Josh, Catherine & Mark ) to achieve the stated goals ),then this time next year the MC will be far healthier.

I will remain invested to see Conneqt Pulse and Conneqt Band launched ... which was always, and remains, the basis of my investment thesis.
Admittedly, the journey to that point has been rockier than expected !

Have a great Christmas break.

All IMO.